[8]Kaplan HG, Malmgren JA, Guo B, Atwood MK. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018. Breast Cancer Res Treat. 2022 Sep;195(2):171-180. [9]Bishop AJ, Ensor J, Moulder SL, et al. Prognosis for patients with metastatic breast cancer wh...
[3]Agostinetto E.Rediti M.Fimereli D.Debien V.Piccart M.Aftimos P.et al.HER2-low breast cancer:molecular characteristics and prognosis.Cancers.2021;13:2824. [4]Prat A.Bardia A.Curigliano G.Hammond M.E.H.Loibl S.Tolaney S.M.et al.An overview of clinical development of agents for...
4 Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y,Ozaki Y, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 2022;2:234e41. https://doi.org/10.10...
[7] Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel) 2021;13(11):2824. [8] Spring LM, Barlow WE, Bardia A, et al. Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph no...
[2] Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan 1; 28(1):92-8. [3] Swain SM et al.,Lancet Oncol. 2020;21(4):519-530...
2 Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M,Aftimos P, et al. HER2-Low breast cancer: molecular characteristics and prognosis. Cancers 2021;13(11). https://doi.org/10.3390/cancers13112824. 3 Alves FR, Gil L, Vasconcelos de Matos L, Baleiras A, Vasques C,Neves ...
[5]Yoon KH, Park Y, Kang E, et al. Effect of estrogen receptor expression level and hormonal therapy on prognosis of early breast cancer[J]. Cancer Res Treat, 2021 [Ahead of print]. [6]Chen T, Zhang N, Moran MS, et al. Borderline ER-positive primary breast cancer gains no signific...
291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world settingdoi:10.1016/j.annonc.2021.08.574J-S. FrenelA. LusqueA. MailliezT. BachelotL. UwerM.A. Mouret ReynierC. Levy...
2021年6月24日,罗氏制药中国宣布,国家药品监督管理总局正式批准创新靶向药物赫赛莱 ® (英文商品名:Kadcyla ® ,通用名:注射用恩美曲妥珠单抗),单药治疗接受了紫杉烷类和曲妥珠单抗治疗的HER2阳性、不可切除局部晚期或转移性乳腺癌患者,且患者应具备以下任一情形:既往接受过针对局部晚期或转移性乳腺癌的治疗,或在...
参考文献 Chen JX; Zhou JM; Zhang HQ, et al. Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain. 10.21203/rs.3.rs-1692389/v1. * 本文由阿斯利康提供支持,仅供医疗专业人士参考